only came across LBT relatively recently - amazing the market cap compared to other bio's that dont even have any revenue yet
not too concerned about the .003 issuance on PSY - think ESN, MOT and others had issues at .001?
Didnt stop them tripling, and PSY looks to have more potential than most
also PSY directors took up their entitlements, and then took up another 30 million of the shortfall
